Can NASH be diagnosed, graded, and staged noninvasively?
- PMID: 22824481
- PMCID: PMC3405360
- DOI: 10.1016/j.cld.2012.05.001
Can NASH be diagnosed, graded, and staged noninvasively?
Abstract
Nonalcoholic bland steatosis and nonalcoholic steatohepatitis (NASH) are stages in the spectrum of nonalcoholic fatty liver disease (NAFLD). NASH may progress to end-stage liver disease. Liver biopsy distinguishes between patients with NASH and no NASH and can stage fibrosis. Markers of hepatocyte apoptosis hold promise as noninvasive tests for NASH diagnosis. Several scoring systems that combine routine clinical and laboratory variables and some proprietary panels can assist in predicting fibrosis severity. Noninvasive imaging modalities are reasonably accurate available tools to determine severity of fibrosis in NAFLD, but none of them yet can replace liver biopsy.
Copyright © 2012 Elsevier Inc. All rights reserved.
Conflict of interest statement
References
-
- Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142:711–725. - PubMed
-
- Younossi ZM, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9(6):524–530. e1. quiz e60. - PubMed
-
- Schwimmer JB, et al. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118(4):1388–93. - PubMed
-
- Browning JD, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387–95. - PubMed
-
- Marcos A, et al. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation. 2000;69(11):2410–5. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
